Study of the Commercial Scale SARS-CoV-2 Vaccine Against the Pilot Scale Among Adults, and Bridging Study of the Immunogenicity in Elderly Against That in Adults

Inclusion Criteria:

1. Healthy adults aged 18-59 or elderly aged ≥60 years;

2. Proven legal identity.

Exclusion Criteria:

1. Travel/residence history of communities with reported cases within 14 days before
trial;

2. History of exposure to Novel Coronavirus infection (nucleic acid positive) within 14
days prior to the trial;

3. Exposed to patients with fever or respiratory symptoms from communities with reported
cases within 14 days prior to the trial;

4. Two or more cases of fever and/or respiratory symptoms in a small area such as home,
office, school and class within 14 days prior to the trial;

5. History of SARS-CoV-2 infection;

6. History of asthma, history of allergy to vaccines or vaccine ingredients, and severe
adverse reactions to vaccines, such as urticaria, dyspnea, and angioneurotic edema;

7. Congenital malformations or developmental disorders, genetic defects, severe
malnutrition, etc.;

8. Autoimmune disease or immunodeficiency/immunosuppression;

9. Patients with serious chronic diseases, serious cardiovascular diseases, uncontrolled
hypertension and diabetes, liver and kidney diseases, malignant tumors, etc.;

10. Serious neurological disorder (epilepsy, convulsions or convulsions) or psychosis;

11. History of thyroid disease or thyroidectomy, absence of spleen, functional absence of
spleen, and absence of spleen or splenectomy caused by any circumstance;

12. Coagulation dysfunction (such as coagulation factor deficiency, coagulation disease,
platelet abnormality) or obvious bruising or coagulation disorder diagnosed by
doctors;

13. Immunosuppressive therapy, cytotoxic therapy, inhaled corticosteroids (excluding
corticosteroid spray therapy for allergic rhinitis, and surface corticosteroid therapy
for acute non-complicated dermatitis) in the past 6 months;

14. Long history of alcohol or drug abuse;

15. Received blood products within 3 months prior to receiving the vaccine;

16. Received other research drugs within 30 days prior to receiving the vaccine;

17. Received live attenuated vaccine within 14 days prior to receiving the vaccine;

18. Received subunit or inactivated vaccine within 7 days prior to receiving the vaccine;

19. Onset of various acute or chronic diseases within 7 days prior to the study;

20. Axillary temperature of >37.0℃ before inoculation of the vaccine;

21. Those who are already pregnant (including a positive urine pregnancy test) or are
breastfeeding, planning to become pregnant within 2 months;

22. In the opinion of the investigator, the participants had any other factors that made
them unsuitable to participate in the clinical trial.